Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 53% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 8/9 — financially strong with improving fundamentals
- ROE of 9.9% — below-average profitability
- Dividend yield of 3.2%
Medtronic plc (MDT) is a Healthcare company operating in Electromedical & Electrotherapeutic Apparatus, listed on the NYSE , with a market capitalisation of $112.0 billion . Key value metrics: P/E ratio 23.1, P/B ratio 2.29, Piotroski F-Score 8 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Medtronic plc — Fundamental Analysis Summary
Medtronic plc (MDT) is currently trading 53% above its Graham Number of $56.95, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 23.1x.
On financial health, MDT shows a strong Piotroski F-Score of 8/9, indicating improving fundamentals across profitability, leverage, and efficiency, and modest return on equity of 9.9% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.00.
StockPik's composite Value Score for MDT is 99/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
MDT reports a high gross margin of 65.3% (sector average: 33.5%) and a solid operating margin of 17.9%.
MDT shows revenue growing at 4% year-over-year, with earnings growing at 27%.
MDT pays a solid dividend yield of 3.2%.